RxDoctor Payments Data

Zoran Murko, MD

Psychiatry · Boca Raton, FLNPI 1740244474

Payments from drug & device makers

$1,712in general payments, 2019–2025

Across 21 payments — averaging $81.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$832
  • AbbVie$333
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$239
  • Neurocrine Biosciences, Inc.$114
  • Teva Pharmaceuticals USA, Inc.$113
  • Alkermes, Inc.$80

What the payments were for

  • Food & beverage$1,712100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,712 in reported general payments places this provider in the 65th percentile of 2,059 psychiatry providers in Florida.

See all psychiatry providers in Florida

Medicare billing

Part B allowed, 2024
$134,656
Medicare patients
112
Services billed
1,383

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole34$56,444
Fluphenazine Hcl24$9,975
TrintellixVortioxetine Hydrobromide11$6,997
Escitalopram Oxalate127$5,654
CymbaltaDuloxetine Hcl12$5,466
Vilazodone Hcl16$3,017
Desvenlafaxine Succinate ErDesvenlafaxine Succinate46$2,992
Rivastigmine14$2,726
Bupropion XlBupropion Hcl66$2,044
Mirtazapine73$1,986
Ramelteon20$1,982
Duloxetine Hcl55$1,471
Olanzapine23$1,360
Venlafaxine Hcl ErVenlafaxine Hcl17$1,187
Divalproex Sodium ErDivalproex Sodium15$1,098

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$832$56,44434 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,059 psychiatry providers in Florida.

Other psychiatry in Boca Raton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →